Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (9033)	3/9/1999 3:45:00 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

Opal, I just get sick and tired of people coming on this board claiming woe is me, I dunno nothing, ask alot of questions, then acting like they don't know difference between morbidity and mortality. Insult to injury after they spread misinformation, they act like they are really "worried about the stock." Give me a break! Hey, if you and webhead want to buy into to it fine but count me out. No one has been more critical about Xoma than me. I was the one suggesting class action lawsuit against Xoma not long ago, remember? In my opinion we still have grounds for a suit in regard to how we have been mislead by Xoma.

To: opalapril who wrote (9033)	3/9/1999 4:09:00 PM
From: Chris Boylan	Respond to of 17367

from opalapril on Mar 9 1999 2:59PM EST I'm guessing this is what you were referring to? It's a quote from the faq apparently. It's from message 7273. Was this additional review part of the original statistical plan for the trial? (9/98) The protocol allows the DSMB to recommend additional reviews (as they did in March when they recommended the September interim analysis). An additional review gives the DSMB the opportunity to take a final look at the results. If the trial design requires any final adjustments, we can make them. If the data are sufficiently positive, we can get a head start with the regulatory authorities.